Heart scans could uncover silent damage in liver patients awaiting transplant
NCT ID NCT06327308
First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time
Summary
This pilot study is testing whether cardiac MRI can detect and track heart muscle scarring in people with cirrhosis who are waiting for a liver transplant. Researchers want to see if inflammation from the liver disease affects the heart, and whether a transplant can reverse that damage. Sixty participants will undergo MRI scans before and after their transplant to monitor changes in the heart muscle.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- cardiac MRI
- What this could lead to
- If successful, this could help doctors detect and monitor heart problems in people with cirrhosis, potentially improving care before and after liver transplant.
- What could go wrong
- This is a small pilot study with only 60 participants, so results may not apply to everyone. MRI scans can be uncomfortable and may not be suitable for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2025
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Inclusion of cirrhotic patients who are candidates for liver transplantation and without documented contraindications to transplantation * Women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing age, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches) * Signature of an informed consent form indicating that the subject has understood the purpose and procedures required by the study and that he or she agrees to participate in the study and to comply with the requirements and restrictions inherent in the study * Patient with a social security system or beneficiary of such a system. Exclusion Criteria: * Minor or over 70 years old * Transplant Patient * Patient with a TIPS * Known heart disease including portopulmonary hypertension and coronary artery disease (history of ischemic heart disease with necrosis, history of cardiomyopathy or acute myocarditis) * Uncontrolled hypertension with interventricular septal thickness ≥ 15 mm * Hemodynamic instability * Type 1 diabetes * Current bacterial infection * HIV infection (or unknown HIV status) * Contraindications for MRI including pacemaker, implantable defibrillators, electrosystolic pacing probe, Swan-Ganz probe, postoperative epicardial electrodes, Starr-Ewards metal ball valves, insulin pumps, ferromagnetic vascular clips, ocular and otological implants, ocular ferromagnetic foreign bodies, renal failure with a GFR \< 30 mL/min/1.73 m², contraindication to contrast media, patient unable to maintain apnea for a few seconds, claustrophobia * Inability to receive informed information in patients with severe encephalopathy who do not have a trusted person * Patient under guardianship, curatorship, Legal incapacity or limited legal capacity * Patient deprived of liberty * Pregnant woman or breastfeeding * Subject unlikely to cooperate in the study and/or low cooperation anticipated by the investigator * Subject being in the period of exclusion from another study or provided for by the "national volunteer file"
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cirrhosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
4 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHRU Nancy - Hôpital de Brabois
RECRUITINGNancy, 54000, France
-
CHU Besancon - Hopital Minjoz
RECRUITINGBesançon, 25000, France
-
CHU Dijon - Hopital François Mitterrand
RECRUITINGDijon, 21000, France
-
CHU Strasbourg - Hopital de HautePierre
NOT_YET_RECRUITINGStrasbourg, 67000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A phase 1 Open-Label, Single-Dose, Parallel-Group study of the pharmacokinetics and safety of VIR-2218 and VIR-3434 monotherapy and combination therapy in adult participants with hepatic impairment
- POCUS guided fluid resuscitation in cirrhosis
- Can a Weight-Loss drug ease pressure in cirrhosis?
- Can a blood pressure pill rescue failing kidneys in cirrhosis?
- Can we spot cancer before it starts? a massive study aims to find out
- Can everyday drugs shield the liver from Cirrhosis's worst threats?